- Home
- LAZ vs MRUS Comparison
LAZ vs MRUS Comparison
Compare LAZ & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LAZ | MRUS |
|---|---|---|
| Founded | 1848 | 2003 |
| Country | United States | Netherlands |
| Employees | 3263 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.1B |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LAZ | MRUS |
|---|---|---|
| Price | $54.44 | $96.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $54.88 | ★ $94.94 |
| AVG Volume (30 Days) | 842.7K | ★ 1.4M |
| Earning Date | 10-23-2025 | 10-31-2025 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $3,016,853,000.00 | $56,606,000.00 |
| Revenue This Year | $0.33 | $56.08 |
| Revenue Next Year | $18.34 | N/A |
| P/E Ratio | $21.75 | ★ N/A |
| Revenue Growth | N/A | ★ 57.54 |
| 52 Week Low | $31.97 | $33.19 |
| 52 Week High | $58.07 | $96.28 |
Technical Indicators
Market Signals| Indicator | LAZ | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | 69.94 | 69.74 |
| Support Level | $49.28 | $95.83 |
| Resistance Level | $51.49 | $96.27 |
| Average True Range (ATR) | 1.75 | 0.29 |
| MACD | 0.71 | -0.29 |
| Stochastic Oscillator | 97.92 | 82.81 |
Price Performance
Historical ComparisonAbout LAZ Lazard Inc.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.